109 related articles for article (PubMed ID: 3912232)
21. Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin.
Gómez J; Freire E
J Mol Biol; 1995 Sep; 252(3):337-50. PubMed ID: 7563055
[TBL] [Abstract][Full Text] [Related]
22. Lower homologues of ahpatinin, aspartic protease inhibitors, from a marine Streptomyces sp.
Sun Y; Takada K; Nogi Y; Okada S; Matsunaga S
J Nat Prod; 2014 Jul; 77(7):1749-52. PubMed ID: 24960234
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the proteolytic activity firmly attached to yeast phoshoenolpyruvate carboxykinase.
Beck I; Müller M; Holzer H
Biochim Biophys Acta; 1982 Jul; 705(2):163-6. PubMed ID: 7052135
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human napsin A.
Cronshaw RF; Schauer-Vukasinovic V; Powell DJ; Giller T; Bur D; Kay J
Protein Pept Lett; 2003 Feb; 10(1):35-42. PubMed ID: 12625824
[TBL] [Abstract][Full Text] [Related]
25. Purification and properties of a pepstatin-insensitive carboxyl proteinase from a gram-negative bacterium.
Oda K; Sugitani M; Fukuhara K; Murao S
Biochim Biophys Acta; 1987 Mar; 923(3):463-9. PubMed ID: 3548827
[TBL] [Abstract][Full Text] [Related]
26. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.
Parikh S; Liu J; Sijwali P; Gut J; Goldberg DE; Rosenthal PJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2207-9. PubMed ID: 16723585
[TBL] [Abstract][Full Text] [Related]
27. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A.
Zaidi N; Burster T; Sommandas V; Herrmann T; Boehm BO; Driessen C; Voelter W; Kalbacher H
Biochem Biophys Res Commun; 2007 Dec; 364(2):243-9. PubMed ID: 17937927
[TBL] [Abstract][Full Text] [Related]
28. Leukocyte protease activities in myotonic dystrophy: studies on effects of protease inhibitors.
Goto I; Shinno N; Kuroiwa Y
Eur Neurol; 1987; 26(2):126-8. PubMed ID: 3549315
[TBL] [Abstract][Full Text] [Related]
29. Spin-labeling of porcine pepsin and Rhizopus chinensis acid protease by diazoketone reagents.
Nakayama S; Nagashima Y; Hoshino M; Moriyama A; Takahashi K; Uematsu Y; Watanabe T; Yoshida M
Biochem Biophys Res Commun; 1981 Jul; 101(2):658-62. PubMed ID: 6796077
[No Abstract] [Full Text] [Related]
30. Aspartic proteinases and inhibitors for their control in health and disease.
Kay J; Jupp RA; Norey CG; Richards AD; Reid WA; Taggart RT; Samloff IM; Dunn BM
Adv Exp Med Biol; 1988; 240():1-11. PubMed ID: 3072839
[No Abstract] [Full Text] [Related]
31. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor.
Katoh I; Yasunaga T; Ikawa Y; Yoshinaka Y
Nature; 1987 Oct 15-21; 329(6140):654-6. PubMed ID: 2821409
[TBL] [Abstract][Full Text] [Related]
33. Pepstatin-insensitive carboxyl proteinases.
Oda K; Murao S
Adv Exp Med Biol; 1991; 306():185-201. PubMed ID: 1812706
[No Abstract] [Full Text] [Related]
34. Evidence that aspartic proteinase is involved in the proteolytic processing event of procathepsin L in lysosomes.
Nishimura Y; Kawabata T; Furuno K; Kato K
Arch Biochem Biophys; 1989 Jun; 271(2):400-6. PubMed ID: 2658811
[TBL] [Abstract][Full Text] [Related]
35. A new way of looking at aspartic proteinase structures: a comparison of pepsin structure to other aspartic proteinases in the near active site region.
Andreeva NS; Bochkarev A; Pechik I
Adv Exp Med Biol; 1995; 362():19-32. PubMed ID: 8540318
[No Abstract] [Full Text] [Related]
36. Characterization and inhibition of the retroviral HIV-proteinase.
von der Helm K; Seelmeir S; Junker U
Biol Chem Hoppe Seyler; 1990 May; 371 Suppl():277-81. PubMed ID: 2205239
[No Abstract] [Full Text] [Related]
37. Subsite preferences of pepstatin-insensitive carboxyl proteinases from bacteria.
Narutaki S; Dunn BM; Oda K
J Biochem; 1999 Jan; 125(1):75-81. PubMed ID: 9880800
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
[TBL] [Abstract][Full Text] [Related]
39. Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation.
Yoshida H; Okamoto K; Iwamoto T; Sakai E; Kanaoka K; Hu JP; Shibata M; Hotokezaka H; Nishishita K; Mizuno A; Kato Y
J Biochem; 2006 Mar; 139(3):583-90. PubMed ID: 16567424
[TBL] [Abstract][Full Text] [Related]
40. Evolution in the structure and function of aspartic proteases.
Tang J; Wong RN
J Cell Biochem; 1987 Jan; 33(1):53-63. PubMed ID: 3546346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
